Seeking Alpha

Optimer Pharmaceuticals (OPTR +15%) says its board of directors has begun exploring a full range...

Optimer Pharmaceuticals (OPTR +15%) says its board of directors has begun exploring a full range of strategic alternatives and has engaged JPMorgan and Centerview Partners as financial advisers. The board stated however, that there are no assurances that the review will result in any action and that there would be no further comment on the process until it's completed. The company also preannounced Q4 results of $0.02 per share, and appointed its chairman, Dr. Henry McKinnell, as CEO.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs